Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $430.36 Analyst target: $685.22 Upside: 59.22%
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.